Physician profile
Amy E Wilmes
NPI 1417242819
$2,312.30
in general payments reported to CMS, 2019-2025
32 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $845 · 2023: $358 · 2024: $296 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.02 | 2021-2025 | |
| Mylan Specialty L.P. | $286.21 | 2021-2024 | Yupelri |
| Novo Nordisk INC | $212.28 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $153.90 | 2021-2024 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $101.98 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.73 | 2021-2024 | |
| Daiichi Sankyo INC. | $69.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.56 | 2021 | |
| Viatris Specialty LLC | $45.67 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $44.68 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $42.42 | 2021-2022 | |
| Insulet Corporation | $39.74 | 2022 | |
| Covis Pharma Gmbh | $37.64 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34.19 | 2021 | |
| Glaxosmithkline, LLC. | $28.48 | 2021-2023 | Shingrix |
| Astellas Pharma US INC | $28.44 | 2021 | |
| Ironshore Pharmaceuticals INC. | $28.32 | 2022 | |
| Becton, Dickinson and Company | $27.21 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $25.07 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.09 | 2025 | Acthar |
| Neurocrine Biosciences, INC. | $14.60 | 2024 | Ingrezza |
| Sanofi Pasteur INC. | $14.57 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.32 | 2023 | Austedo Xr |
| Dexcom, INC. | $14.05 | 2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $13.91 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.83 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $13.75 | 2023 | |
| Seqirus USA INC | $12.89 | 2022 | |
| Acadia Pharmaceuticals INC | $11.77 | 2022 | |
| Tactile Systems Technology INC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wilmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.